Therapy Trends Updates - Page 1

Learn More Targeted Therapies In Asthma: Update Bulletin # 1 [April 2019]

This edition presents the views and insights from three of the world's foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the severe asthma market, including: the EMA's CHMP...

Compare
Learn More Psoriasis: Update Bulletin # 3 [April 2019]

This edition presents the views and insights from three of the world's foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the psoriasis market. Topics covered include opinions...

Compare
Learn More Prostate Cancer : Update Bulletin # 2 [April 2019]

This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Bristol-Myers Squibb announcing positive interim data from the CheckMate 650 assessing...

Compare
Learn More Future Innovations in Oncology : Update Bulletin # 3 [April 2019]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in future innovations in oncology, including: ImmunoGen announcing that their...

Compare
Learn More Renal Cell Carcinoma: Update Bulletin # 3 [March 2019]

This edition presents the views and insights from three of the world's foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the renal cell carcinoma (RCC) market, including: the FDA...

Compare
Learn More Non-Hodgkin Lymphoma: Update Bulletin # 2 [March 2019]

This edition presents key opinion leader (KOL) views on recent developments in the Non-Hodgkin Lymphoma (NHL) market. Topics covered include: Roche announcing that the US FDA had granted priority review for polatuzumab...

Compare
Learn More Multiple Myeloma: Update Bulletin # 3 [March 2019]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of multiple myeloma (MM). Topics covered include KOL views on Karyopharm Therapeutics' submission, in January 2019, of a...

Compare
Learn More Gastric Cancer: Update Bulletin # 3 [March 2019]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the gastric cancer (GC) market, including: initiation of BeiGene's two...

Compare
Learn More Diabetes Early Stage Outlook: Update Bulletin # 2 [March 2019]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the diabetes mellitus (DM) market. Within this update, KOLs provided their...

Compare
Learn More Colorectal Cancer : Update Bulletin # 2 [March 2019]

This edition presents key opinion leader (KOL) views on recent developments in the colorectal cancer (CRC) market. Topics covered include: Gritstone Oncology announcing that the FDA had granted Fast Track designation to...

Compare
Learn More Non-Small Cell Lung Cancer (NSCLC): Update Bulletin # 2 [February 2019]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the non-small cell lung cancer (NSCLC) market. KOLs...

Compare
Learn More Nonalcoholic Steatohepatitis (NASH): Update Bulletin # 3 [February 2019]

Topics covered include expert opinions on: GENFIT’s announcement of the initiation of a Phase II proof-of-concept clinical trial evaluating nitazoxanide in patients with NASH-induced fibrosis; Madrigal...

Compare
Learn More Multiple Sclerosis: Update Bulletin # 1 [February 2019]

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the multiple sclerosis (MS) market, including: Initiation of...

Compare
Learn More Melanoma: Update Bulletin # 1 [February 2019]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the melanoma market. KOLs gave their candid...

Compare
Learn More Chronic Lymphocytic Leukaemia: Update Bulletin # 2 [February 2019]

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the chronic lymphocytic leukaemia (CLL) market, including:...

Compare
Learn More Breast Cancer: Update Bulletin # 3 [February 2019]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the European Commission’s (EC) approval for an...

Compare

Browse by